Paper No. \_\_\_\_ Date Filed: July 29, 2016

#### Filed On Behalf Of:

Novartis AG

By:

Nicholas N. Kallas NKallas@fchs.com ZortressAfinitorIPR@fchs.com (212) 218-2100

#### UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BRECKENRIDGE PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS AG,

Patent Owner.

Case IPR2016-01103

Patent No. 5,665,772

PATENT OWNER'S PRELIMINARY RESPONSE UNDER 37 C.F.R. § 42.107



## TABLE OF CONTENTS

<ul> <li>III. Summary Of The Asserted Grounds</li> <li>III. Petitioners Fail To Explain Why A Person Of Ordinary Skill Would Rely On Yalkowsky If The Goal Was To Increase Rapamycin's Water Solubility</li> <li>A. Petitioners' Assumption That Yalkowsky Applies To Rapamycin's Water Solubility Is Unsupported And Incorrect</li> <li>B. Petitioners' Conclusory And Unsupported Assertions Cannot Remedy The Deficiencies In Their Analysis Or Give Rise To A Genuine Issue Of Material Fact</li> <li>IV. Petitioners Fail To Explain Why Lemke Would Have Motivated One Of Ordinary Skill To Synthesize Everolimus Or To Have Reasonably Expected Everolimus To Be More Water Soluble Than Rapamycin</li> </ul>	
Would Rely On Yalkowsky If The Goal Was To Increase Rapamycin's Water Solubility	3
Rapamycin's Water Solubility Is Unsupported And Incorrect	8
Cannot Remedy The Deficiencies In Their Analysis Or Give Rise To A Genuine Issue Of Material Fact  IV. Petitioners Fail To Explain Why Lemke Would Have Motivated One Of Ordinary Skill To Synthesize Everolimus Or To Have Reasonably Expected Everolimus To Be More Water Soluble Than Rapamycin	8
Motivated One Of Ordinary Skill To Synthesize Everolimus Or To Have Reasonably Expected Everolimus To Be More Water Soluble Than Rapamycin	.14
	.17
A. Petitioners Ignore And Mischaracterize The Differences Between Rapamycin's And Everolimus' C40 Groups	.17
B. Petitioners Offer No Argument Or Evidence To Explain Why One Of Ordinary Skill Would Have Added An Ether And Two Carbons To Rapamycin To Increase Its Water Solubility	.18
V. Petitioners' Attorney Argument Against Pharmaceutical Composition Claim 7 In Ground B Contradicts Petitioners' Own Arguments And Expert Testimony Against The Claimed Compounds	.21
A. Overview	.21
B. Petitioners Advance Contradictory Arguments Regarding The Ability To Formulate Rapamycin Into Pharmaceutical Compositions	22



	C.		
		Authorities Are Inapplicable To The Present Case	26
VI.	Concl	ısion	30



## TABLE OF AUTHORITIES

### **Cases**

Apotex Inc. v. Wyeth LLC, IPR2015-00873, Paper 8 (September 16, 2015)9	, 15
Aventis Pharma Deutschland GmbH v. Lupin Ltd., 499 F.3d 1293 (Fed. Cir. 2007)	, 28
Geneva Pharm. Inc. v. Glaxosmithkline PLC, 189 F. Supp. 2d 377 (E.D. Va. 2002)	, 28
In re Magnum Oil Tools Int'l, Ltd., No. 2015-1300, slip op. (Fed. Cir. July 25, 2016)	, 26
Kimberly-Clark Worldwide, Inc. v. First Quality Baby Prods., LLC., 900 F. Supp.2d 903 (E.D. Wis. 2012)	15
Kimberly-Clark Worldwide, Inc. v. First Quality Baby Prods., LLC., 579 Fed. Appx. 996 (Fed. Cir. 2014)	15
Kinetic Techs., Inc. v. Skyworks Solns., Inc., IPR2014-00529, Paper 8 (September 23, 2014)	14
KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007)	27
Palo Alto Networks, Inc. v. Finjan, Inc., IPR2015-02000, Paper 7 (March 23, 2016)	21
Phillips Petroleum Co. v. Huntsman Polymers Corp., 157 F.3d 866 (Fed. Cir. 1998)	16
Rosco, Inc. v. Mirror Lite Co., 304 F.3d 1373 (Fed. Cir. 2002)	28
Sandt Tech., Ltd. v. Resco Metal and Plastics Corp., 264 F.3d 1344 (Fed. Cir. 2001)	28
Shopkick Inc. v. Novitaz, Inc., IPR2015-00279, Paper 7 (May 29, 2015)9	, 20



Sinskey v. Pharmacia Ophthalmics, Inc., 982 F.2d 494 (Fed. Cir. 1992)	22
Wowza Media Sys., LLC v. Adobe Sys., Inc., IPR2013-00054, Paper 16 (July 13, 2013)	14
Statutes	
35 U.S.C. § 282	28
Other Authorities	
81 Fed. Reg. 18750 (April 1, 2016)	16, 17
Rules	
37 C.F.R. § 42.104	8
37 C.F.R. § 42.108	16
37 C.F.R. § 42.65	14



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

